Theriva Biologics Advances VCN-01 Dosing Trial for Metastatic Pancreatic Cancer — Theriva Biologics, Inc.

Event summary

First patient dosed in VIRAGE2 Phase 2a trial evaluating more frequent dosing of VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC).
Trial builds on positive data from VIRAGE Phase 2b study showing improved survival with VCN-01 and standard-of-care chemotherapy.
Enrollment expected to complete by H2 2026, with initial data anticipated by Q3 2027.
Study aims to refine dosing regimen for potential pivotal Phase 3 trial.

The big picture

Theriva Biologics is advancing its oncolytic adenovirus VCN-01 through a critical Phase 2a trial, aiming to optimize dosing for metastatic pancreatic cancer. The study follows positive survival data from earlier trials and regulatory feedback suggesting repeated dosing could enhance clinical benefits. Pancreatic ductal adenocarcinoma remains a high-unmet-need indication, with limited treatment options beyond standard chemotherapy.

What we're watching

Clinical Efficacy: Whether more frequent dosing of VCN-01 will enhance tumor stroma degradation and antitumor immune response.
Regulatory Pathway: How the VIRAGE2 data will inform the design of a potential Phase 3 trial and shape discussions with EMA and FDA.
Strategic Expansion: The pace at which Theriva Biologics can leverage repeated dosing to improve outcomes in combination with other cancer therapies.